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Abstract 
Background: CD4+ T cells play an important role in the initiation of an immune response by providing help to other 
cells. Among the helper T subsets, interferon‑γ (IFN‑γ)‑secreting T helper 1 (Th1) and IL‑17‑secreting T helper 17 (Th17) 
cells are indispensable for clearance of intracellular as well as extracellular pathogens. However, Th1 and Th17 cells 
are also associated with pathogenesis and contribute to the progression of multiple inflammatory conditions and 
autoimmune diseases.
Results: In the current study, we found that BJ‑1108, a 6‑aminopyridin‑3‑ol analogue, significantly inhibited Th1 and 
Th17 differentiation in vitro in a concentration‑dependent manner, with no effect on proliferation or apoptosis of acti‑
vated T cells. Moreover, BJ‑1108 inhibited differentiation of Th1 and Th17 cells in ovalbumin (OVA)‑specific OT II mice. 
A complete Freund’s adjuvant (CFA)/OVA‑induced inflammatory model revealed that BJ‑1108 can reduce generation 
of proinflammatory Th1 and Th17 cells. Furthermore, in vivo studies showed that BJ‑1108 delayed onset of disease 
and suppressed experimental autoimmune encephalomyelitis (EAE) disease progression by inhibiting differentiation 
of Th1 and Th17 cells.
Conclusions: BJ‑1108 treatment ameliorates inflammation and EAE by inhibiting Th1 and Th17 cells differentiation. 
Our findings suggest that BJ‑1108 is a promising novel therapeutic agent for the treatment of inflammation and 
autoimmune disease.
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Background
CD4+ T cells play an important role in adaptive immunity 
by orchestrating other immune cells [1]. Upon antigenic 
exposure, naïve CD4+ T cells undergo differentiation 
and expansion of distinct effector subsets, which play a 
major role in mediating immune responses through the 
secretion of specific cytokines [2, 3]. The differentiation 
of naïve CD4+ T cells begins with antigenic stimulation, 
which results in interactions between the T cell recep-
tor (TCR), with CD4 as a co-receptor, and the antigen-
MHC II complex presented by antigen presenting cells 
(APCs) [3]. TCR signaling induces downstream signal-
ing that leads to proliferation and differentiation of naïve 
CD4 T cells into effector cells [4]. Lineage-specific dif-
ferentiation depends upon TCR signaling, the cytokine 
environment, and co-stimulatory molecules that direct 
differentiation of naïve CD4+ T cells into IFN-γ-secreting 
T-helper 1 (Th1), IL-4-secreting T-helper 2 (Th2), IL-
17-secreting T-helper 17 (Th17), and IL-10-secreting 
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regulatory T (Treg) cells [1, 5]. Th1 cells participate in 
the elimination of intracellular pathogens and regula-
tion of organ-specific autoimmune diseases [1]. Similarly, 
Th17 cells enhance immune responses against extracel-
lular pathogens, particularly bacteria and fungi, as well 
as tissue inflammation [2, 6]. Nevertheless, unrestrained 
activation of Th1 and Th17 cells is associated with auto-
immune and inflammatory disorders such as multiple 
sclerosis, rheumatoid arthritis, and psoriasis [7, 8].
Autoimmune diseases are abnormal immune responses 
in which activation and expansion of autoreactive T cells 
and other inflammatory cells play important roles in tis-
sue inflammation and injury [9, 10]. Multiple sclerosis 
(MS) is one of the most common autoimmune diseases 
of the central nervous system. In MS, inflammatory cells 
infiltrate and demyelinate the axonal tract in the brain 
and spinal cord, disrupting neuronal signaling along 
axons [11]. Finally, neurodegeneration of the brain and 
spinal cord, mediated by CD4+ T cells directed against 
myelin, can result in paralysis [12]. Experimental autoim-
mune encephalomyelitis (EAE) is an animal model of MS 
that mimics the clinical and pathophysiological features 
of human MS [13, 14]. Although the exact cause of MS is 
unclear, it is thought to be mediated by a combination of 
genetic and environmental factors [10, 15–17]. Although 
Th1 cells are considered to be the primary effector T 
cells in EAE pathology, EAE can occur in IFN-γ knock-
out mice [18]. Previous studies have shown that Th17 
cells that secrete IL-17 and IL-23 are also important to 
the development of EAE [19–21]. Altogether, the stud-
ies provide evidence that both proinflammatory Th1 and 
Th17 cells are associated with pathogenesis of autoim-
mune diseases like multiple sclerosis and rheumatoid 
arthritis [22, 23]. MS affects more than 2 million people 
worldwide. A number of chemotherapeutic and immu-
notherapeutic agents have been approved as MS disease-
modifying therapies [24–27]. However, these therapies 
are associated with serious side effects and frequent 
response failures, and safe medications to manage auto-
immune and inflammatory diseases are still needed.
Previous studies have shown that BJ-1108, an ana-
logue with a phenyl group attached to a 6-amino moiety 
strongly inhibits angiogenesis and tumor growth [28, 
29]. Inflammation is one of the major pathophysiologi-
cal characteristics of autoimmune disease and is asso-
ciated with oxidative stress and reduction in cellular 
antioxidant capacity [30]. 6-Amino-2,4,5-trimethylpyri-
din-3-ol analogues have been reported to show antioxi-
dant and antiangiogenic activity [31, 32]. Furthermore, 
Timilshina et  al. reported that a 2,4,5-trimethylpyridin 
derivative inhibits Th1 and Th17 differentiation and sub-
sequently ameliorates EAE progression [33]. These find-
ings prompted us to examine whether BJ-1108 could be 
used to treat an inflammatory autoimmune disease like 
MS, using an EAE model.
We investigated the therapeutic potential of a novel 
derivative (6-amino-2,4,5-trimethylpyridin-3-ol; BJ-1108) 
on inflammation and autoimmune disease. We found 
that BJ-1108 significantly suppressed Th cell function by 
inhibiting Th1 and Th17 differentiation and marginally 
decreased proliferation of activated T cells without apop-
tosis. Further, we found that BJ-1108 treatment reduced 
Th1 and Th17 generation in a complete Freund’s adjuvant 
(CFA)/OVA-immunized inflammatory model. Further-
more, BJ-1108 treatment delayed the onset of EAE and 
alleviated ongoing EAE by reducing infiltration of mon-
onuclear cells into the central nervous system (CNS), as 
well as decreased Th1 and Th17 cells in the spleen, drain-
ing lymph nodes (dLNs), and CNS of EAE-affected mice.
Results
BJ‑1108 inhibits differentiation of Th1 and Th17 cells
Based on reports that 6-aminopyridin-3-ol analogues 
inhibit oxidative stress and inflammation [29], we exam-
ined whether BJ-1108 is involved in autoimmunity and 
inflammatory immune responses. CD4+ T cells are 
essential to an immune response, and Th1 and Th17 cells 
have been extensively studied to understand inflamma-
tion and autoimmune diseases [34, 35]. Inhibiting dif-
ferentiation of naïve CD4+ T cells into proinflammatory 
Th1 and Th17 cells helps to mitigate autoimmune disease 
[36]. To test the inhibitory effect of BJ-1108 on Th1 and 
Th17 differentiation, purified splenic CD4+ T cells were 
cultured in Th1 and Th17-polarizing conditions with 
cytokine stimulation and TCR ligation by anti-CD3 and 
anti-CD28 for 3  days. Under Th1-polarizing conditions, 
approximately 54% of CD4+ T cells were IFN-γ+ in the 
untreated control group, and BJ-1108 treatment signifi-
cantly inhibited Th1 differentiation by as much as 37%. In 
addition, up to a 50% reduction group in Th17 differen-
tiation was observed in the BJ-1108-treated mice. There-
fore, BJ-1108 (10  μM) treatment significantly reduced 
IFN-γ+ and IL-17+ cells differentiation on day 3 after 
in  vitro stimulation with TCR and cytokines (Fig.  1a). 
To further investigate the regulatory effects of BJ-1108 
on CD4+ T cells differentiation, CD4+ T cells stimu-
lated by TCR and cytokines were treated with varying 
concentrations of BJ-1108. BJ-1108 treatment decreased 
the percentage of IFN-γ+ Th1 and IL-17+ Th17 cells in 
a concentration-dependent manner (Fig. 1b). These data 
suggest that BJ-1108 significantly decreased differentia-
tion of Th1 and Th17 cells.
BJ‑1108 inhibits antigen‑specific CD4+ T cell differentiation
To examine whether BJ-1108 can inhibit antigen-specific 
Th1 and Th17 differentiation of CD4+ T cells, we used 
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ovalbumin (OVA)-specific OT-II TCR transgenic mice. 
OT-II CD4+ T cells express transgenic alpha-chain and 
beta-chain TCRs that are specific for chicken OVA 323–
339 in the context of MHC class II [37]. Naïve CD4+ T 
cells were isolated from spleens and lymph nodes (LNs) 
of OT-II TCR transgenic mice and cultured with BJ-1108 
in the presence of OVA peptide and APCs for 3  days. 
Consistent with Fig. 1a, BJ-1108 inhibited generation of 
IFN-γ+ CD4+ T cells by 30% and IL-17+ CD4+ T cells by 
50% (Fig. 2a). To examine the effects of BJ-1108 on OVA-
specific Th1 and Th17 differentiation, OT-II CD4+ T cells 
were treated with various concentrations of BJ-1108 in 
the presence of OVA peptide and APCs. The percentage 
of IFN-γ-producing Th1- and IL-17-producing Th17 cells 
was decreased in a concentration-dependent manner by 
BJ-1108 (Fig.  2b). Generation of IL-17-secreting Th17 
cells was suppressed more than IFN-γ-secreting Th1 cells 
by treatment with BJ-1108. Thus, BJ-1108 can directly 
inhibit differentiation of antigen-specific T cells.
BJ‑1108 has no significant effect on T cell proliferation
To test whether the regulatory effect of BJ-1108 on Th 
cell differentiation is mediated by cytotoxicity or reduced 
proliferation, we checked the effect of our compound 
on apoptosis and proliferation of CD4+ T cells. CD4+ 
T cells were isolated and cultured under anti-CD3 and 
anti-CD28 stimulation in the presence or absence of 
BJ-1108 for 3  days. On day 3 after activation, apoptosis 
was assessed with Annexin-V and propidium iodide (PI) 
staining. The percentages of viable cells were comparable 
between untreated cells and those treated with various 
concentrations of BJ-1108 (Fig.  3a). Next, carboxyfluo-
rescein succinimidyl ester (CFSE)-labeled CD4+ T cells 
were cultured with various concentrations of BJ-1108 in 
Fig. 1 BJ‑1108 inhibits CD4+ T cell differentiation. a Naïve CD4+ T cells isolated from spleens and draining lymph nodes were stimulated under 
Th1‑ and Th17‑polarizing conditions in the presence or absence of 10 μM BJ‑1108 for 72 h. Cells were then re‑stimulated with phorbol 12‑myristate 
13‑acetate, ionomycin, and GolgiStop for 4 h, followed by intracellular cytokine staining and flow cytometry. b Th1 and Th17 differentiation with 
multiple concentrations of BJ‑1108. Representative data (mean ± SEM) of three independent experiments are shown. **p < 0.001 and ***p < 0.0001 
versus vehicle
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Th1- and Th17-polarizing conditions for 3  days. Based 
on CFSE dilution, treatment with different concentra-
tions of BJ-1108 demonstrated a slight decrease in Th1 
and Th17 cell proliferation (Fig.  3b). However, decrease 
in proliferation was negligible compared to BJ-1108-me-
diated differentiation. Furthermore, in  vitro prolifera-
tion measured by thymidine analog bromodeoxyuridine 
(BrdU) labeling assay demonstrated that BJ-1108 treat-
ment slightly decreased proliferation under Th1-polariz-
ing conditions (Fig. 3c). Similarly, Ki-67, a nuclear protein 
indicating cell proliferation, was analyzed after 3 days of 
culture under Th1-polarizing conditions. Proliferation 
of IL-12-treated cells increased in a manner relative to 
that of cells not treated with cytokine, whereas BJ-1108 
treatment reduced the rate of Ki-67 expression to less 
than 10% of that in cells not treated with the compound 
(Fig.  3d). Altogether, these data suggest that although 
BJ-1108 slightly affects CD4+ T cell proliferation, but 
that inhibition of Th cell differentiation is not a result of 
reduced proliferation or increased apoptosis.
BJ‑1108 reduces the inflammatory response in CFA/
OVA‑immunized mice
Th1 and Th17 cells are critical for the progression and 
pathology of inflammation and autoimmune diseases [8]. 
Inhibition of Th1 and Th17 cell differentiation in vitro by 
BJ-1108 prompted us to examine whether this compound 
could inhibit inflammatory responses initiated by IFN-γ 
and IL-17A. Mice were administrated OVA (2 mg/ml) in 
CFA by intraperitoneal injection. CFA/OVA administra-
tion induced inflammation through the generation of 
Th1 and Th17 cells. BJ-1108 (1 mg/kg) was injected every 
day for up to 4  days, and mice were sacrificed on day 5. 
We found that the size of spleens, lymph node (LN) and 
Fig. 2 BJ1108 negatively regulates CD4+ T cells differentiation without antigen specificity. Naïve CD4+ T cells and antigen presenting cells isolated 
from spleen and LNs of OT‑II mice. Cells were cultured under Th1‑ and Th17‑polarizing conditions with OVA323–339 (0.1 μM) in the presence or 
absence of a a single concentrations (10 μM) or b multiple concentrations of BJ‑1108. Cells were then re‑stimulated with phorbol 12‑myristate 
13‑acetate, ionomycin, and GolgiStop for 4 h, followed by intracellular cytokine staining and flow cytometry. Representative data (mean ± SEM) of 
three independent experiments are shown. *p < 0.01 and ***p < 0.0001 versus vehicle
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draining lymph nodes (dLNs) in BJ-1108-treated CFA/
OVA-immunized mice were smaller than those in mice 
immunized with CFA/OVA alone (Fig.  4a). Furthermore, 
Th cells from spleens and LNs of CFA/OVA-immu-
nized mice that received either BJ-1108 or no treat-
ment were analyzed. The results showed that CFA/OVA 
administration promoted IFN-γ and IL-17A generation as 
compared to no CFA/OVA immunized mice, and BJ-1108 
treatment inhibited generation of IFN-γ and IL-17A in 
LNs and spleens in CFA/OVA immunized mice (Fig.  4b, 
c). Thus, BJ-1108 inhibits inflammation by reducing IFN-
γ-producing Th1 and IL-17A-producing Th17 cells in vivo.
Fig. 3 BJ‑1108 partially inhibits CD4+ T cell proliferation without apoptosis. a Naïve CD CD4+ T cells and antigen‑presenting cells (APCs) isolated 
from spleen and lymph nodes (LNs). Apoptosis was analyzed by Annexin‑V and propidium iodide staining after cells were cultured in Th1‑differen‑
tiating conditions for 72 h, followed by flow cytometry. The percentages of live cells are shown. b Naïve CD4+ T cells and APCs isolated from spleen 
and LNs. CFSE‑labeled naïve CD4+ T cells were cultured under Th1‑ (left panel) and Th17‑ (right panel) polarizing conditions. Histogram shows cell 
proliferation analyzed by CFSE dilution using flow cytometry. Bar graphs indicate the percentage of CFSE+CD4+ T cells. c Naïve CD4+ T cells and 
APCs isolated from spleen and LNs were cultured under Th1‑polarizing conditions with BrdU (10 μM) in the presence or absence BJ‑1108 (10 μM) for 
72 h. Cells were analyzed by flow cytometry. Bar graphs indicate the percentage of BrdU+CD4+ T cells. d Naïve CD4+ T cells and APCs isolated from 
spleen and LNs were cultured under Th1‑polarizing conditions in the presence or absence BJ‑1108 (10 μM) for 72 h. Bar graphs indicate the percent‑
age of Ki‑67+CD4+ T cells. Representative data from three independent experiments are shown. *p < 0.01 and **p < 0.001 versus untreated group
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BJ‑1108 attenuates EAE pathology by negatively 
regulating inflammatory T cells
The finding that BJ-1108 inhibited Th1 and Th17 differ-
entiation in vitro and reduced inflammation by decreas-
ing IFN-γ-producing Th1 and IL-17A-producing Th17 
cells in vivo prompted us to investigate whether BJ-1108 
treatment affects the development of inflammatory auto-
immune disease. To address this question, we employed 
the EAE model, a well-established model of MS, because 
Th1 and Th17 cells are critical for the progression and 
pathology of MS [21]. To investigate the possible pro-
tective role of BJ-1108 in the development of EAE, we 
immunized female C57BL/6 mice with MOG35−55 pep-
tide emulsified with CFA and pertussis toxin as described 
in “Methods” section. Vehicle or BJ-1108 (1 mg/kg) was 
administrated intraperitoneally every other day begin-
ning 1 day after immunization. The severity of the result-
ing paralysis was assigned a disease score. All mice in 
the vehicle-treated group developed severe EAE with a 
mean peak clinical score of 3.5, whereas BJ-1108-treated 
mice showed delayed disease onset and significantly 
diminished EAE severity, with a 2.6 mean peak clini-
cal score (Fig.  5a). The total cell number from spleen 
and CNS were also decreased in drug treated EAE mice 
(Fig.  5b). Furthermore, CNS-infiltrated mononuclear 
cells were enriched by density gradient centrifugation 
and analyzed by flow cytometry. As depicted in Fig.  5c, 
significantly reduced infiltration of CD4+ T cells, CD8+ 
T cells, B220+ B cells, and CD11b+ macrophages/micro-
glia was observed in the brains and spinal cords of BJ-
1108-treated EAE mice. Because autoreactive CD4+ T 
cells, especially Th1 and Th17 cells, are critical to the 
induction of EAE, we analyzed Th cells in EAE mice. 
As expected, BJ-1108 treatment significantly reduced 
IFN-γ-secreting Th1 and IL-17-secreting Th17 cells in 
spleens, dLNs, and CNS of EAE-induced mice (Fig. 5d). 
These data suggest that BJ-1108 is effective in amelio-
rating ongoing EAE by restricting Th1 and Th17 cell 
differentiation.
Discussion
Our study demonstrated BJ-1108 suppression of Th1 
and Th17 cell differentiation with no effect on prolifera-
tion and apoptosis of activated T cells in  vitro. BJ-1108 
restricted CFA/OVA-induced inflammation by reduc-
ing IFN-γ-producing Th1 and IL-17A-producing Th17 
cells in  vivo. Furthermore, BJ-1108 treatment allevi-
ated inflammatory infiltration and reduced leakage of 
mononuclear cells from the blood brain barrier. Mice 
that received BJ-1108 treatment displayed lower EAE 
scores and better clinical recovery from EAE. Moreover, 
BJ-1108 administration reduced the frequencies of Th1 
and Th17 cells in the spleens, LNs, and spinal cords of 
EAE mice.
CD4+ Th cells play an important role in activating 
and directing other immune cells [1]. IFN-γ secretion-
induced Th1 cell differentiation depends on signaling 
through IFN-γ receptor, IL-12 receptor and their down-
stream signaling transcription factor signal transducer 
and activator of transcription 1 (STAT1) and STAT4. 
Likewise, IL-17-producing Th17 cell differentiation is ini-
tiated after IL-6 stimulation and subsequent activation 
of STAT3 [36]. These proinflammatory Th1 and Th17 
Fig. 4 Suppression of inflammation in vivo by BJ‑1080 in complete 
Freund’s adjuvant/ovalbumin (CFA/OVA)‑immunized mice. Acute 
inflammation was induced in 8‑ to 12‑week‑old C57BL/6 mice by 
intraperitoneal immunization with OVA in CFA, and then 1× PBS 
or 1 mg/kg BJ‑1108 was administered intraperitoneally each day. a 
Images of spleens, lymph nodes, and draining lymph nodes (dLNs) 
from CFA/OVA‑immunized mice treated or untreated with BJ‑1108 
after 4 days. CD4+ T cells from b dLNs and c spleens were re‑stimu‑
lated with phorbol 12‑myristate 13‑acetate and ionomycin for 4 h, fol‑
lowed by measurement of IFN‑γ‑ and IL‑17A‑producing CD4+ T cells 
by flow cytometry. Numbers in the dot plots represent percentages 
of Th1 and Th17 cells. The mean ± SEM of five independent experi‑
ments is shown. #p < 0.01 versus vehicle. *p < 0.01 and **p < 0.001 
versus CFA/OVA‑treated group
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Fig. 5 BJ‑1108 ameliorates the onset and development of experimental autoimmune encephalomyelitis (EAE) by attenuating the generation of 
Th1 and Th17 cells. Acute EAE was induced in 8‑ to 12‑week‑old C57BL/6 mice by subcutaneous immunization with MOG35–55 in complete Freund’s 
adjuvant and pertussis toxin. Mice were administered 1 mg/kg BJ‑1108 or vehicle intraperitoneally each day. a Clinical scores were assigned daily. 
b Total cell count in spleen and CNS of drug treated and untreated EAE mice. c Twenty‑four days later, total mononuclear cells were isolated from 
brains and spinal cords of mice and analyzed by flow cytometry. Total percent of infiltrated CD4+ T cells, CD8+ T cells CD11+ cells and B220+ cells 
in CNS. d 24 days later, lymphocytes from spleen, LNs, and spinal cords were re‑stimulated with phorbol 12‑myristate 13‑acetate and ionomycin for 
4 h, followed by measurement of IFN‑γ‑ and IL‑17A‑producing CD4+ T cells using flow cytometry. Numbers in the dot plots represent percentages of 
Th1 and Th17 cells. The mean ± SEM of five independent experiments is shown. *p < 0.01 and **p < 0.001 versus vehicle
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cells are key mediators of inflammation and the develop-
ment of autoimmune disease. Th1- and Th17-associated 
cytokines have a significant impact on inflammation in 
the brain and severity of disease [38, 39]. The attenua-
tion of inflammation in BJ-1108-treated mice was asso-
ciated with a decrease in the differentiation of Th1 and 
Th17 cells and therefore a reduction in IFN-γ and IL-17 
cytokine expression in spleens, lymph nodes and CNS.
CD4+ T cell responses to antigen are instructed by 
innate immune factors. The environment in which APCs 
initially encounter antigens is associated with specific 
adjuvants. Presentation of processed antigen with co-
stimulatory molecules and a precise combination of 
cytokines drives differentiation of naïve CD4+ T cells 
toward a specific effector lineage, including that of Th1, 
Th2 and Th17 cells [40]. Therefore, we used an OVA-
based mouse inflammatory disease model in which OVA 
combined with CFA, a potent Th1/Th17 skewing adju-
vant, induced a powerful Ova-specific Th1 and Th17 
inflammatory immune response. BJ-1108 treatment 
inhibited inflammation of CFA/OVA-induced mice by 
negatively regulating differentiation of IFN-γ+ Th1 and 
IL-17+ Th17 cells.
EAE, an animal model of human MS, is mediated 
by autoreactive T cells that secrete pro-inflammatory 
cytokines in the CNS, leading to inflammation and demy-
elination [11, 12, 41]. Th1 cells have been considered the 
primary effector T cells in the pathology of EAE and MS 
[8, 42, 43]. However, accumulating evidence reveals that 
both Th1 and Th17 cells are crucial for autoimmune dis-
ease [8, 22, 44, 45]. Proinflammatory cytokines such as 
IFN-γ and IL-17, secreted by Th1 and Th17 cells, cause 
inflammation, and are primary causes for aggravation 
autoimmune disorder [44]. Therefore, investigating drugs 
that target Th1 and Th17 cells to manage autoimmune 
diseases has clinical significance. We provide in vitro and 
in vivo evidence that BJ-1108 represses the development 
of Th1 and Th17 cells and ameliorates EAE. BJ-1108 
treatment significantly reduced the generation of Th1 
and Th17 cells in spleens, dLNs, and CNS of EAE mice 
at the peak of disease. However, APCs such as micro-
glia, astrocytes, macrophages, and B cells act as the first 
line of defense against infection or inflammation and can 
participate in self-destructive mechanisms by secreting 
inflammatory factors and/or presenting myelin epitopes 
to autoreactive T cells [46]. How BJ-1108 affects myeloid 
cell function is unknown; however, a significant reduc-
tion in infiltrating CD11b+ macrophages/microglia and 
B220+ B cells in the brain and spinal cord suggests that 
BJ-1108 may regulate myeloid cells by regulating T cell 
function.
The antioxidant effects of 6-amino-2,4,5-trimeth-
ylpyridin-3-ol scaffold have been reported in several 
studies [31, 32]. Recently, BJ-1108 was shown to signifi-
cantly inhibit angiogenesis and reactive oxygen species 
(ROS) production in cancer cells [29]. T cells, especially 
Th1 and Th17 cells, function in tumor immunity by 
secreting cytokines and transcription factors [47]. ROS 
produced in response to NOX-2 are associated with 
the differentiation of T cells, but are not required for T 
cell activation or proliferation [48]. The current study 
revealed anti-inflammatory activities of BJ-1108 in an 
inflammatory disease model, mediated by a reduction in 
Th1 and Th17 cell differentiation. NOX-2-derived ROS 
are associated with T cells differentiation, but do not 
affect T cell proliferation and activation [48–50]. Bonini 
et  al. reported that administration of ROS scavengers 
reduced EAE lethality in negative regulator of ROS 
(NRROS)-knockout mice [51]. NRROS interacts with 
NOX-2 and maintains its stability [51]. BJ-1108 signifi-
cantly inhibits NOX-2-derived ROS, which may lead to 
reduced Th1 and Th17 differentiation [29]. Altogether, 
the studies suggest that the effects of BJ-1108 on T cell 
differentiation correlate with inhibition of NOX-2-de-
rived ROS and subsequently ameliorate inflammation 
and autoimmune disease.
In conclusion, the current study revealed the therapeu-
tic potential of BJ-1108 for inflammation and autoim-
mune diseases. BJ-1108 treatment reduced the severity of 
inflammation and EAE disease by inhibiting differentia-
tion of naïve CD4+ T cells into Th1 and Th17 cells. How-
ever, because previous studies have indicated that Th1 
and Th17 differentiation is caused by inhibition of NOX-
2-derived ROS, further research is needed to define the 
precise target of BJ-1108. Collectively, these data imply 
that BJ-1108 could be a promising therapeutic compound 
for the management of Th1- and Th17-mediated inflam-
mation and autoimmune disease.
Methods
Mice
C57BL/6 mice were maintained in pathogen-free condi-
tions at the Animal Center of Yeungnam University. The 
gradual fill method of CO2 inhalation was used to eutha-
nize mice with minimal pain. No animals died during 
the study. Animal experiments were approved by Insti-
tutional Animal Care and Use Committee (IACUC) of 
Yeungnam University (Approval No: 2015-029).
Intracellular cytokine staining and flow cytometry
CD4+ T cells were collected and re-stimulated for 4  h 
with phorbol 12-myristate 13-acetate (PMA) (50  ng/
ml; Sigma) and ionomycin (750  ng/ml; Calbiochem, La 
Jolla, CA, USA) with GolgiStop (BD Biosciences). Cells 
were stained with anti-mouse CD4-FITC (GK1.5; Bio-
Legend, San Diego, CA, USA), anti-mouse B220-PE/
Page 9 of 11Kang et al. Biol Res  (2017) 50:8 
Cy7 (RA3-6B2; BioLegend), anti-mouse CD3 ε-APC 
(145-2C11; BioLegend), anti-mouse CD8a-PE/Cy7 (53-
6.7; BioLegend), anti-mouse IFN- γ-PE (XMG1.2; Bio-
Legend), and anti-mouse IL-17A-APC (TC11-18H10.1; 
BioLegend) according to the manufacturer’s instructions. 
Data were obtained with a FACSVerse (BD Immunocy-
tometry System, San Jose, CA, USA) and analyzed using 
FlowJo software.
In vitro T cell differentiation assay
Naïve CD4+ T cells were positively selected from 
spleens and LNs using anti-CD4 microbeads (Miltenyi 
Biotec, Auburn, CA, USA). CD8+ cells were depleted 
using anti-CD8 microbeads (Miltenyi Biotec), and 
the remaining cells were regarded as APCs. CD4+ T 
cells and APCs were cultured in complete RPMI 1640 
medium containing 10% fetal bovine serum (FBS) and 
1% penicillin and streptomycin. For antigen-specific 
stimulation, isolated naïve CD4+ T cells (2 × 105) and 
APCs ((1 × 105) from OT-II mice were incubated with 
OVA323–339 peptide (0.1  μM) under Th1-polarizing 
conditions (10  ng/ml IL-12; BioLegend, 5  μg/ml anti-
IL-4; BioLegend), Th17-polarizing conditions (1  ng/
ml TGF-β1; R&D Systems, 10  ng/ml IL-6; R&D Sys-
tems, 5 μg/ml anti-IL-4; BioLegend, 5μ/ml anti–IFN-γ; 
BioLegend).
T cell proliferation assays
Naïve CD4+ T cells were purified using microbe-
ads (Miltenyi Biotec), followed by labeling with CFSE 
(eBioscience) in a 37  °C water bath for 15 min. CFSE-
labeled naïve CD4+ T cells were stimulated with anti-
CD3 (5 μg/ml) and anti-CD-28 (1 μg/ml) antibodies in 
Th1- and Th17-polarizing conditions. After 3 days, cell 
proliferation was measured with CFSE dye dilutions 
using flow cytometry. For 5-bromo-2′-deoxyuridine 
(BrdU) labeling, naïve CD4+ T cells from spleens and 
LNs were cultured under Th1-polarizing conditions 
with BrdU (10  μM). After 3  days, cells were stained 
using a BrdU kit according to the manufacturer’s proto-
col (BD Biosciences). For Ki-67 detection, naïve CD4+ 
T cells were cultured under Th1-polarizing conditions 
and stained with phycoerythrin-conjugated Ki-67 (Bio-
Legend). BrdU and Ki-67 were measured using flow 
cytometry.
Apoptosis assay
Naïve CD4+ T cells were purified using microbeads 
(Miltenyi Biotec) and cultured under Th1-polarizing con-
ditions with anti-CD3 (5 μg/ml) stimulation. After 3 days, 
apoptosis was assessed by staining for Annexin V-APC 
and PI according to the manufacturer’s protocol (BD Bio-
sciences), followed by flow cytometry.
Immunization
To induce an inflammatory response, 6 to 8-week-old 
mice were immunized intraperitoneally with 2  mg/ml 
OVA and an equal volume of CFA in the presence or 
absence of 1  mg/kg BJ-1108 daily. After 5  days, spleens 
and dLNs were collected and analyzed by flow cytom-
etry. To induce EAE, 6 to 8-week-old mice were immu-
nized subcutaneously with 6  mg/ml MOG35–55 peptide 
(MEVGWYRSPFSRVVHLYRNGK) emulsified in CFA 
containing 5 mg/ml Mycobacterium tuberculosis H37RA 
(Difco). Mice were injected intraperitoneally with 250 ng 
pertussis toxin (List Biological Laboratories) on the day 
of immunization and 48  h later. Mice were monitored 
daily, and disease was scored as follows: 0  =  normal; 
1 =  limp tail; 2 = paraparesis (limp tail and incomplete 
paralysis of one or two hind limbs); 3 = paraplegia (limp 
tail and complete paralysis of two hind limbs); 4 = para-
plegia with forelimb weakness or paralysis; 5  =  mori-
bund appearance or death. One milligram per kilogram 
BJ-1108 in phosphate-buffered saline (PBS) or PBS only 
(vehicle) were administered intraperitoneally on day 0 
and every other day subsequently.
Statistical analysis
Data are expressed as the mean ± SEM. Student’s t test 
or one-way ANOVA were used to assess the significance 
of differences between experimental groups using Prism 
software (GraphPad).
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